AHR and chronic kidney disease: Importantly, in this study, AHR inhibitor and STUB-1 activator ameliorated the effects of IS on a thrombotic phenotype without affecting bleeding time, suggesting that targeting CKD-specific mechanisms can result in safer antithrombotics [88].